Market experts anticipate the stock to list at a premium of up to 25 percent over its issue price, driven by the company’s ...

Ben Lamm, CEO of Colossal Biosciences, wanted to ensure his brand was approachable to all, fun, educational and full of ...

Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech company back home in China. In a ...

Windtree Therapeutics, a Nasdaq listed biotechnology company, has plans to raise up to $200 million to build a treasury of ...

A species of huge, flightless bird that once inhabited New Zealand disappeared around 600 years ago, shortly after human ...

Niagen Bioscience CEO Robert Fried discusses the science of NAD, the problems with the supplement industry, and how his company is leading the way in anti-aging research.

Caribou Biosciences' allogeneic CAR T-cell therapies show promising early efficacy and safety, but require clinical ...

Jasper Therapeutics started the year with 64 full-time employees and a robust valuation of more than $320 million. Just seven ...

Northwest Control Systems, LLC, is nearly set to open up shop from its new location in Chehalis at 582 S. Market Blvd. The company, which currently operates in Rochester, purchased the building in May ...

Akoya Bioscience: Something Special For Investing In A Spatial Bioscience Company Jan. 26, 2023 3:13 PM ET Akoya Biosciences, Inc. (AKYA) Stock A , AKYA 9 Comments 3 Likes Looking For Diogenes ...

Harvard Bioscience, Inc. will be disclosing its financial results for Q1 2025, providing transparency and insights into its performance. The scheduled conference call aims to engage with investors ...

Harvard Bioscience, Inc. (NASDAQ:HBIO) Q4 2024 Earnings Call Transcript March 12, 2025 Harvard Bioscience, Inc. beats earnings expectations. Reported EPS is $0.06, expectations were $0.05.